Regentis Biomaterials Ltd. (RGNT)
Makes injectable gels that repair damaged cartilage and tissue.
$1.78-0.14%Healthcare
StockGlow Score
Leaning Bearish
BearishBullish
1 year ago-76.2%
The outlook
RGNT is trading near its 52-week low with price well below its long-term moving averages, reflecting weak recent momentum. Analyst coverage leans heavily bullish on valuation—the average price target sits roughly 462% above the current price—though the stock itself shows limited upside in its technical trend. Overall sentiment remains bearish despite the disconnect between targets and current price action.
What’s behind the score
Price trendBelow its 50- & 200-day averages
52-week range4% of the way from its 52-week low to high
Price targetAvg target +462% vs current price
Market cap
$12.5M
52-wk high
$15.50
52-wk low
$1.23
50-day avg
$2.88
200-day avg
$4.07
Trailing P/E
—